Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574597 · ClinicalTrials.gov registry record · Phase 3
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 17,604
- Enrollment target
NCT03574597: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT03574597 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 17,604 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2183% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03574597, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17,604 participants
- Enrollment target
Study Summary
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.
Primary Outcome
Number of participants with first occurrence of composite outcome measure consisted of CV death (undetermined cause of death presumed CV death), non-fatal MI, or non-fatal stroke are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with pa
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,604 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 3 |
What the finished NCT03574597 record still lists
NCT03574597 is an interventional study that assigns participants to a tested intervention. Its 17,604 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2183% higher).
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT03574597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03574597 about?
NCT03574597 is a clinical study titled "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity". The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the...
What is the current status of trial NCT03574597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17,604 participants. The study started on 2018-10-24. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT03574597?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03574597?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03574597's enrollment target sits among peer trials
17,604 11th of 2000 higher than 1,990 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07290361 · 17,587 participants · NA
Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)
- NCT06272110 · 17,500 participants
Promoting Equitable Access to Language Services in Health and Human Services
- NCT07108660 · 17,800 participants · NA
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI